Literature DB >> 3921089

Effects of the C5a anaphylatoxin and its relationship to cyclo-oxygenase metabolites in rabbit vascular strips.

T E Hugli, F Marceau.   

Abstract

Strips of rabbit blood vessels were suspended in vitro and responses to complement peptides C3a and C5a were recorded isotonically. Human C3a (up to 1.5 microM) was inactive on rabbit vascular strips. Human C5a (2.9-59 nM) decreased spontaneous activity of the rabbit portal vein under resting baseline tension. The C5a relaxed strips of portal vein and pulmonary artery that were precontracted with noradrenaline (NA, 200 nM). On the portal vein, C5a-induced relaxation was preceded by a transient contractile phase which decreased with repeated applications of C5a. The magnitude of C5a-induced relaxation of both vessels increased with repeated stimulation by C5a. Maximal levels of relaxation for the third application of C5a at 59 nM averaged 44% and 17% of the NA-induced contraction plateau in portal vein and pulmonary artery, respectively. Strips of rabbit aorta responded minimally to C5a. Indomethacin (5.6 microM) significantly inhibited C5a-induced relaxation of the portal vein and pulmonary artery but had no effect on the early contractile response of the portal vein. Mepyramine (10 microM) failed to modify the C5a response from either vessel, but it reduced the contractile phase of the C5a response on the portal vein when applied in conjunction with indomethacin. The drug SKF 88046, an end organ antagonist of thromboxane (TX) A2 and some contractile prostaglandins, reduced the contractile phase and increased relaxation of the portal vein to C5a but did not modify the response of the pulmonary artery. Radioimmunoassays for 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and TXB2 were performed on the fluid bathing rabbit isolated blood vessels. C5a promoted release of 6-keto-PGF1, over the basal release rate in rabbit tissues. Only trace quantities of TXB2 were produced by rabbit vessels exposed to C5a. 7 It is concluded that the mechanical response of blood vessels to C5a is mainly determined by the type of cyclo-oxygenase products released and by the sensitivity of each blood vessel to these active lipids. Tissue histamine release is also responsible for a component of the response of rabbit portal vein to C5a. The relaxant effect of C5a on rabbit blood vessels may be a phenomenon related to the previously reported hypotensive action of classical anaphylatoxins in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921089      PMCID: PMC1987148          DOI: 10.1111/j.1476-5381.1985.tb16155.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Actions of anaphylatoxin on circulation and respiration of the guinea pig.

Authors:  G Bodammer; W Vogt
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

2.  The nature of adrenergic mechanisms involved in anaphylatoxin activity in the guinea-pig.

Authors:  R Hicks; A C Sackeyfio
Journal:  Br J Pharmacol       Date:  1972-10       Impact factor: 8.739

3.  Prostaglandins as potentiators of increased vascular permeability in inflammation.

Authors:  T J Williams; J Morley
Journal:  Nature       Date:  1973-11-23       Impact factor: 49.962

4.  Prostaglandin action on the main pulmonary artery and portal vein of the rabbit.

Authors:  K Kitamura; H Suzuki; H Kuriyama
Journal:  Jpn J Physiol       Date:  1976

5.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation.

Authors:  C V Wedmore; T J Williams
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

6.  A new bioassay for glucagon.

Authors:  G Gagnon; D Regoli; F Rioux
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

7.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

8.  C5a-induced tracheal contraction: effect of an SRS-A antagonist and inhibitors of arachidonate metabolism.

Authors:  J F Regal; R J Pickering
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

9.  Anaphylatoxin-induced shock and two patterns of anaphylactic shock: hemodynamics and mediators.

Authors:  K Pavek; P J Piper; G Smedegård
Journal:  Acta Physiol Scand       Date:  1979-04

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

View more
  6 in total

1.  Effects of low molecular weight fibrin degradation products 6A and 6D on rabbit aorta strips.

Authors:  F Marceau; J Bouthillier; B Tremblay; S St-Pierre
Journal:  Agents Actions       Date:  1987-10

2.  C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes.

Authors:  C Lundberg; F Marceau; T E Hugli
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

3.  Cloning and preliminary pharmacological characterization of the anaphylatoxin C5a receptor in the rabbit.

Authors:  D R Bachvarov; S Houle; M Bachvarova; J Bouthillier; S A St-Pierre; Y Fukuoka; J A Ember; F Marceau
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

4.  Prostacyclin biosynthesis and reduced 5-HT uptake after complement-induced endothelial injury in the dog isolated lung.

Authors:  H Bult; J J Heiremans; A G Herman; C M Malcorps; F A Peeters
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

5.  Eicosanoids and histamine mediate C5a-induced electrolyte secretion in guinea pig ileal mucosa.

Authors:  J F Kachur; S Won-Kim; C Anglin; T S Gaginella
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

6.  The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo.

Authors:  W A Schumacher; J C Fantone; S E Kunkel; R C Webb; B R Lucchesi
Journal:  Agents Actions       Date:  1991-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.